ClinicalTrials.Veeva

Menu

A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo

Novo Nordisk logo

Novo Nordisk

Status and phase

Enrolling
Phase 1

Conditions

Overweight
Obesity

Treatments

Drug: NNC0487-0111
Behavioral: LED
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT07757087
NN9490-8152
2025-522744-40 (Other Identifier)
U1111-1324-2934 (Other Identifier)
2025

Details and patient eligibility

About

The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity or overweight following weight loss. This will be compared with the amount of energy used by participants who achieve weight loss through a low-calorie diet and by participants receiving placebo (without weight loss).

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or older at the time of signing the informed consent.

Exclusion criteria

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.
  • Exposure to an investigational medicinal product within 30 days.
  • Any condition, or disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Anticipated change in lifestyle (e.g., eating, exercise or sleeping pattern) during the study, for example, an imminent job change to/from a physically demanding occupation.
  • Claustrophobia or severe discomfort of being confined in small rooms.
  • History of type 1 or type 2 diabetes mellitus.
  • Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal (GI), or endocrinological conditions.
  • Unusual meal habits (including, but not limited to, eating disorders) and special diet requirements or unwillingness to eat the food provided in the study.
  • Use of any weight lowering pharmacotherapy or pharmacotherapy that may cause weight gain, including systemic corticosteroids (except for a short course of treatment, i.e., 7-10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilisers 6 months prior to screening.
  • Use of incretin or amylin-based therapies prior to screening or previous discontinuation of long-term incretin and/or amylin-based therapy due to tolerability issue.
  • Physical activity of moderate to vigorous intensity for greater than (>) 4 hours/week within the past 6 months before screening.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

120 participants in 3 patient groups, including a placebo group

NNC0487-0111
Experimental group
Description:
Participants will receive once weekly subcutaneous injection of NNC0487-0111.
Treatment:
Drug: NNC0487-0111
Placebo
Placebo Comparator group
Description:
Participants will receive once weekly subcutaneous injection of placebo matched to NNC0487-0111.
Treatment:
Drug: Placebo
Low Energy Diet (LED)
Other group
Description:
Participants will receive a low-energy dietary designed to achieve a reduction in body weight.
Treatment:
Behavioral: LED

Trial contacts and locations

2

Loading...

Central trial contact

Novo Nordisk

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems